Back to Authors

Luo, Sicheng

https://orcid.org/0009-0006-7729-6921

Mayo Clinic

Chinese Academy of Sciences

Citations 1

Identify Non-mutational p53 Functional Deficiency in Human Cancers
Li, Qianpeng , Zhang, Yang , Luo, Sicheng , Zhang, Zhang , Oberg, Ann L. , Kozono, David , Lu, Hua , Sarkaria, Jann N. , Ma, Lina , Wang, Liguo , Kozono, David E , Wang, Liguo , Sarkaria, Jann N

Genomics, Proteomics & Bioinformatics | September 26, 2024 | Volume: 22 | Issue: 5 | Pages: No page available

10.1093/gpbjnl/qzae064 Get It

Abstract An accurate assessment of p53’s functional statuses is critical for cancer genomic medicine. However, there is a significant challenge in identifying tumors with non-mutational p53 inactivation which is not detectable through DNA sequencing. These undetected cases are often misclassified as p53-normal, leading to inaccurate prognosis and downstream association analyses. To address this issue, we built the support vector machine (SVM) models to systematically reassess p53’s functional statuses in TP53 wild-type (TP53WT) tumors from multiple The Cancer Genome Atlas (TCGA) cohorts. Cross-validation demonstrated the good performance of the SVM models with a mean area under the receiver operating characteristic curve (AUROC) of 0.9822, precision of 0.9747, and recall of 0.9784. Our study revealed that a significant proportion (87%–99%) of TP53WT tumors actually had compromised p53 function. Additional analyses uncovered that these genetically intact but functionally impaired (termed as predictively reduced function of p53 or TP53WT-pRF) tumors exhibited genomic and pathophysiologic features akin to TP53-mutant tumors: heightened genomic instability and elevated levels of hypoxia. Clinically, patients with TP53WT-pRF tumors experienced significantly shortened overall survival or progression-free survival compared to those with predictively normal function of p53 (TP53WT-pN) tumors, and these patients also displayed increased sensitivity to platinum-based chemotherapy and radiation therapy.